AU764061B2 - Use of active P40 conjugates for nasal delivery - Google Patents

Use of active P40 conjugates for nasal delivery Download PDF

Info

Publication number
AU764061B2
AU764061B2 AU29391/99A AU2939199A AU764061B2 AU 764061 B2 AU764061 B2 AU 764061B2 AU 29391/99 A AU29391/99 A AU 29391/99A AU 2939199 A AU2939199 A AU 2939199A AU 764061 B2 AU764061 B2 AU 764061B2
Authority
AU
Australia
Prior art keywords
pro
lys
ser
asn
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU29391/99A
Other languages
English (en)
Other versions
AU2939199A (en
Inventor
Christine Andreoni
Thierry Baussant
Jean-Francois Haeuw
Thien Nguyen
Isabelle Rauly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of AU2939199A publication Critical patent/AU2939199A/en
Application granted granted Critical
Publication of AU764061B2 publication Critical patent/AU764061B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU29391/99A 1998-03-27 1999-03-26 Use of active P40 conjugates for nasal delivery Ceased AU764061B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9803814A FR2776521B1 (fr) 1998-03-27 1998-03-27 Utilisation de conjugues p40 actifs par voie nasale
FR98/03814 1998-03-27
PCT/FR1999/000703 WO1999049892A2 (fr) 1998-03-27 1999-03-26 Utilisation de conjugues p40 actifs par voie nasale

Publications (2)

Publication Number Publication Date
AU2939199A AU2939199A (en) 1999-10-18
AU764061B2 true AU764061B2 (en) 2003-08-07

Family

ID=9524572

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29391/99A Ceased AU764061B2 (en) 1998-03-27 1999-03-26 Use of active P40 conjugates for nasal delivery

Country Status (8)

Country Link
EP (1) EP1066054A2 (fr)
JP (1) JP2002509897A (fr)
CN (1) CN1243569C (fr)
AU (1) AU764061B2 (fr)
BR (1) BR9909180A (fr)
CA (1) CA2324477A1 (fr)
FR (1) FR2776521B1 (fr)
WO (1) WO1999049892A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2798857B1 (fr) * 1999-09-23 2003-06-06 Pf Medicament Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
FR2805163A1 (fr) * 2000-02-21 2001-08-24 Pf Medicament Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
CN1549726A (zh) * 2000-07-31 2004-11-24 耶鲁大学 先天性免疫系统指导的疫苗
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
FR2828106A1 (fr) * 2001-08-02 2003-02-07 Pf Medicament Utilisation d'une omp d'enterobacterie de faible masse moleculaire comme porteur et/ou adjuvant
CN112062820B (zh) * 2020-08-24 2023-05-26 黑龙江八一农垦大学 大肠杆菌重组外膜蛋白a包涵体蛋白的复性纯化方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0433225A1 (fr) * 1989-12-06 1991-06-19 Ciba-Geigy Ag Procédé de préparation d'une protéine (e.g. TGF) à activité biologique
WO1996014415A1 (fr) * 1994-11-07 1996-05-17 Pierre Fabre Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
FR2748476B1 (fr) * 1996-05-07 1998-08-14 Pf Medicament Complexe immunogene, son utilisation, son procede de preparation et vaccin le contenant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0433225A1 (fr) * 1989-12-06 1991-06-19 Ciba-Geigy Ag Procédé de préparation d'une protéine (e.g. TGF) à activité biologique
WO1996014415A1 (fr) * 1994-11-07 1996-05-17 Pierre Fabre Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAULY ET AL, RESEARCH IN IMMUNOLOGY, 1998, 149(1), 99 *

Also Published As

Publication number Publication date
WO1999049892A2 (fr) 1999-10-07
EP1066054A2 (fr) 2001-01-10
CN1243569C (zh) 2006-03-01
CA2324477A1 (fr) 1999-10-07
FR2776521A1 (fr) 1999-10-01
WO1999049892A3 (fr) 2000-03-30
JP2002509897A (ja) 2002-04-02
AU2939199A (en) 1999-10-18
BR9909180A (pt) 2000-12-05
FR2776521B1 (fr) 2000-12-15
CN1301176A (zh) 2001-06-27

Similar Documents

Publication Publication Date Title
US6113911A (en) Peptide fragment of respiratory syncytial virus protein G, immunogenic agent, pharmaceutical composition containing it and preparation method
JP3253327B2 (ja) 髄膜炎菌外層膜蛋白質をコードするヌクレオチド配列を有するポリヌクレオチドおよびワクチン組成物
US6558673B1 (en) Complexes of immunogens derived from RSV surface glycoprotein G covalently coupled to a support molecule
JP4310184B2 (ja) 呼吸器合胞体ウイルス(rsv)gタンパク質のペプチドとワクチンにおけるその利用
JP2003528157A (ja) 結合体ワクチンにおいてキャリアとして使用するためのタンパク質
EP0584167A1 (fr) Adn recombine codant pour un peptide signal, polypeptide d'interaction et sequence d'ancrage de membrane
JP2005511010A6 (ja) 呼吸器合胞体ウイルス(rsv)gタンパク質のペプチドとワクチンにおけるその利用
US6780420B1 (en) Carrier protein having an adjuvant effect, immunogenic complex containing it, process for their preparation, nucleotide sequence and vaccine
JP2002505083A (ja) 組換え脂質化PsaAタンパク質、調製法および使用
AU764061B2 (en) Use of active P40 conjugates for nasal delivery
JP2001515723A (ja) A群連鎖球菌ワクチン
CA1341334C (fr) Peptides synthetiques provenant de la proteine m streptococcique, ainsi que des vaccins prepares a partir de ceux-ci
US20040014661A1 (en) Periplasmic domain of an enterobacterium omp protein and its use as carrier or adjuvant
AU728139B2 (en) Peptide fragment of the respiratory syncytial virus G protein
MXPA00009490A (en) Use of active p40 conjugates for nasal delivery
FR2801219A1 (fr) Procede de preparation de proteine recombinante renaturee en presence de detergent
HK1006674B (en) Synthetic peptides from streptococcal m protein and vaccines prepared therefrom

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)